TMPRSS2-ERG fusions are common genetic events in prostate cancer. Until now, this genetic alteration was modelled by ERG overexpression. In this short communication, we report the creation of mouse prostate organoids that have undergone gene fusion through a CRISPR/Cas9-based strategy. The genetic fusion of TMPRSS2 and ERG results in ERG overexpression. This effect is androgen receptor-mediated, as expression of the fusion transcript can be restored to wildtype ERG levels by treatment with the androgen receptor antagonist Nilutamide.
Victor Tirolle, Adrien Krug, Emma Bokobza, Mattijs Bulcaen, M. Ensinck, Maarten H. Geurts, Delilah Hendriks, F. Vermeulen, Frédéric Larbret, Alejandra Gutiérrez-Guerrero, Louise Medaer, Rik Gijsbers, Philippe Mangeot, Hans Clevers, Marianne S. Carlon, Frédéric Bost, Els Verhoeyen
Rachel S. Lee, Luxi Zhang, Adeline Berger, Mitchell G. Lawrence, Jiangning Song, Birunthi Niranjan, Rebecca G. Davies, Natalie L. Lister, Shahneen Sandhu, Mark A. Rubin, Gail P. Risbridger, Renea A. Taylor, David S. Rickman, Lisa G. Horvath, Roger J. Daly
Benedetta Artegiani, Lisa van Voorthuijsen, Rik G.H. Lindeboom, Daniëlle Seinstra, Inha Heo, Pablo Tapía, Peter J. Peters, Michiel Vermeulen, Hans Clevers
Johanna F. Dekkers, James R. Whittle, François Vaillant, Huei-Rong Chen, Caleb A. Dawson, Kevin Liu, Maarten H. Geurts, Marco J. Herold, Hans Clevers, Geoffrey J. Lindeman, Jane E. Visvader
Discussion(0)
No comments yet. Be the first to comment.